Search Within

Neha Sanat Korde

Formats
  1. Meeting Abstract (158)
  2. Journal Article (63)
  3. Research Letter (7)
  4. Review (3)
  5. Correspondence (2)
  6. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (234)
  2. Department of Medicine (234)
  3. Hematologic Malignancies, Division of (234)
  4. Myeloma (234)
  5. Survivorship Research (234)
  6. Hematologic Malignancies Research (212)

More Groups

People
  1. Sham Mailankody (187)
  2. Alexander Lesokhin (169)
  3. Hani Hassoun (162)
  4. Malin Hultcrantz (151)
  5. Sergio Giralt (144)
  6. Heather Landau (142)

More People

Years
  1. 2025 (2)
  2. 2024 (44)
  3. 2023 (40)
  4. 2022 (34)
  5. 2021 (15)
  6. 2020 (14)

More Years

Publications
  1. Blood (91)
  2. Clinical Lymphoma, Myeloma and Leukemia (47)
  3. Journal of Clinical Oncology (17)
  4. Leukemia and Lymphoma (11)
  5. Biology of Blood and Marrow Transplantation (7)
  6. Blood Cancer Journal (7)

More Publications

Publishers
  1. American Society of Hematology (97)
  2. Elsevier Inc. (60)
  3. American Society of Clinical Oncology (17)
  4. Nature Publishing Group (13)
  5. Taylor & Francis Group (11)
  6. Ferrata Storti Foundation (7)

More Publishers

Results (234)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mutationally enriched regions of the non-coding genome harbor functionally impactful mutations that dysregulate key genes involved in multiple myeloma pathogenesis
    Meeting Abstract

    Blaney, P.; Maclachlan, K. H.; Papadimitriou, M.; Mikulasova, A.; Gagler, D. C.; Braunstein, M. J.; Lahoud, O. B.; Kaminetzky, D.; Wang, Y.; Liu, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1b study of step-up dosing with ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mian, H.; Baljevic, M.; Magen, H.; Gatt, M. E.; Mazza, I. A.; Searle, E.; Lichtman, E. I.; McKay, J. T.; Plesner, T.; Rodriguez, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance
    Meeting Abstract

    Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; GarceĢs, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma
    Meeting Abstract

    Shah, U. A.; Cogrossi, L. L.; Derkach, A.; Castro, F.; Fei, T.; DeWolf, S.; Garces, J. J.; Policastro, A.; Grioni, M.; Sisti, S.; more...
    Blood (2024)

    Fulltext@MSK | Save